ARQTArcutis Biotherapeutics Inc
ARQT
Arcutis Biotherapeutics Inc2,442
Mkt Cap
$2.61BVolume
2.61M52W High
$31.7752W Low
$12.72PE Ratio
-743.31ARQT Fundamentals
Price
$21.11Prev Close
$20.86Open
$20.9750D MA
$22.69Beta
1.48Avg. Volume
1.05MEPS (Annual)
-$0.1269P/B
13.92Rev/Employee
$1.06M$3,587.81
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of...
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 3,172 Shares
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Watanabe sold 3,172 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $74,890.92. Following the sale, the insider owned 720,755...
Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $31,661.01 in Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) CFO Latha Vairavan sold 1,341 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $31,661.01. Following the completion of the transaction, the chief financial...
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 684 Shares of Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 684 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $16,149.24. Following the completion of the...
Arcutis Biotherapeutics Q1 Earnings Call Highlights
Arcutis Biotherapeutics (NASDAQ:ARQT) reported first-quarter 2026 net product revenues of $105.4 million, a 65% increase versus the same period last year, as the company pointed to continued demand growth for its topical therapy ZORYVE and progress across a "grow, expand, build" strategy that includ...
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) has earned a consensus rating of 'Moderate Buy' from the eight brokerages that are covering the firm, MarketBeat.com reports. One...
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 7,144 Shares of Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard Welgus sold 7,144 shares of the firm's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $22.99, for a total value of $164,240.56. Following the completion of the sale...
Pictet Asset Management Holding SA Buys 74,528 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Pictet Asset Management Holding SA lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 566.4% during the fourth quarter, according to the company in its most...
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT
UBS Group AG lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,243,432 shares of the company's stock after acquir...
<
1
2
...
>
Compact View
Not available
Not available